37results about How to "Clear activity" patented technology

The invention discloses a sandworm polypeptide enteric capsule. A sandworm polypeptide capsule is used as an antioxidant material which is applied to eliminating human body free radicals and is absorbed in a weak basic environment in the intestinal tract, so that the absorption rate and the bioavailability are improved. The sandworm polypeptide is extracted by steps of sandworm washing, enzyme hydrolysis, microfiltration, dialysis and the like. Then, the sandworm polypeptide powder is used together with mannitol, magnesium stearate and sodium deoxycholate to prepare the enteric capsule. The sandworm polypeptide enteric capsule provided by the invention has the antioxidant function, can eliminate human body free radicals, and is high in bioavailability and extremely easy to absorb.

The invention relates to a compound with effects of resisting inflammation and platelet activation and aggregation as well as a preparation method and application thereof. The compound has the structure of (25R)-26-oxy-beta-D-glucopyranose-5alpha-furostanol-3beta,12beta,22,26-tetraalcohol-3-oxy-beta-D-glucopyranose(1->2)[beta-D-glucopyranose(1->3)]-beta-D-glucopyranose(1->4)-beta-D-galapyranoside. The effects of the compound in the field of cardial vessels are comprehensively researched from platelet aggregation, platelet activation, platelet calcium ion variation, platelet activation signal transduction pathway and expression of platelet activation relevant inflammatory factors in the invention for the first time. Results show that the compound is a substance found to be with a strong effect on resisting platelet aggregation so far in the allium macrostemon saponin compounds, which has the stronger effect than that of aspirin with the same concentration; and the compound simultaneously has an obvious effect on resisting relevant platelet inflammations. The compound provided by the invention can be applied to medicines for treating thrombus and atherosclerosis.

The invention discloses a preparation and an application of an anti-inflammatory effective part of rhaponticum uniflorum. The preparation method comprises the following main steps: carrying out reflux extraction on rhaponticum uniflorum with ethyl alcohol, and recovering ethyl alcohol; separating an alcohol extract with D101 or AB-8 macroporous resin; and eluting with 50%-90% ethyl alcohol, and concentrating and drying an eluant, so as to obtain the anti-inflammatory effective part of the rhaponticum uniflorum. The anti-inflammatory effective part of the rhaponticum uniflorum disclosed by the invention has relatively good anti-inflammatory activity on acute and chronic inflammations, and is simple in process and suitable for industrialized production.

The invention discloses a pancreas cancer prevention use of polycyclic fused macrocyclic lactam compounds. The structural formula of the polycyclic fused macrocyclic lactam compounds is shown in the description; and in the formula, R1 is OCH3 or H, R2 is Cl or OH, and R3 is OCH3 or H. The polycyclic fused macrocyclic lactam compounds are separated through separating and purifying a fermentation liquid of Streptomyces xiamenensis CGMCC No.4.3534 from mangrove soil. Prepared ikarugamycin and derivatives thereof can inhibit proliferation and vitality of human pancreas cancer cells, and can be used to prepare pancreas cancer prevention drugs.

The invention provides a ligustrazine substituted benzoic acid derivative with a general formula structure 1. The compound comprises a substituent group substituting a benzoic acid mother nucleus and containing a ligustrazine structure, the general structural formula is represented as the formula 1, wherein R1 is selected from any one of -H or 3,5,6-trimethyl ligustrazine-2-methylene; R2 is selected from any one of -H, -OH, 3,5,6-trimethyl ligustrazine-2-methyleneoxy or 3,5,6-trimethyl ligustrazine-2-formyloxy; R3 is selected from any one of -H, -OH, -OCH3, 3,5,6-trimethyl ligustrazine-2-methyleneoxy or 3,5,6-trimethyl ligustrazine-2-formyloxy; R4 is selected from any one of -H, -OH, 3,5,6-trimethyl ligustrazine-2-methyleneoxy or 3,5,6-trimethyl ligustrazine-2-formyloxy; at least one of R1-R4 is the substituent group containing the ligustrazine structure. The invention further provides a preparation method of the derivative and an application in preparation of drugs for treating brain nerve injury and sequelae of brain nerve injury.

The invention belongs to the field of water and soil pollution prevention and control, and particularly relates to a method for acquiring relative abundance and activity of whole-course ammoxidation microorganisms from a complex environment system based on a macro omics technology. Through metagenome / metatranscriptome sequencing and bioinformatics processing, whole-course ammoxidation microbial genomes and transcripts are extracted from microbial communities with complex environments, the relative abundance, activity and community structure characteristics of whole-course ammoxidation microorganisms in a system are determined, a complete picture of a group metabolic potential model is constructed, and the potential contribution of the microorganisms to the nitrogen conversion process is determined. The method has the characteristics of high flux, high sensitivity and high accuracy, does not need to enrich and culture microorganisms, has an in-situ characteristic, is suitable for large-scale sampling investigation and research, and has important significance on optimization of a nitrification management strategy in a specific region.

An extracellular material in freeze-dried form obtained from skeletal cells which has osseoinductive bone repair and regeneration activity in vivo, and compositions and methods involving the material.

The invention discloses a method for preparing hydrogen peroxide by using a covalent organic framework catalyst to catalyze oxygen reduction, and belongs to the field of electrocatalysis. According to the invention, thieno [3, 2-b] thiophene-2, 5-dicarboxaldehyde (DTDA) is used as a linear construction unit, and 4, 4 ', 4'-tetramethyl-4, 4 ', 4'-tetramethyl-4, according to the preparation method, the COFs material constructed by taking 3, 4 ', 4'-(1, 3, 5-triazine-2, 4, 6-triyl) triphenylamine (TTT), tris (4-aminophenyl) amine (TAPA) and tris (4-aminophenyl) benzene (TAPB) as central constructs respectively is used as a catalyst, oxygen reduction preparation of hydrogen peroxide with high oxygen reduction activity, stability and hydrogen peroxide selectivity is realized, the operation is simple, the controllability is strong, and certain universality is realized.

The invention specifically relates to application of the enzymatic hydrolysates of total glycosides of grosvenor momordica fruit to preparation of drugs or / and health products used for preventing or / and treating hepatic fibrosis, belonging to the technical field of prevention and treatment of hepatic fibrosis. The invention discloses novel pharmaceutical application of the enzymatic hydrolysates of total glycosides of grosvenor momordica fruit, i.e., application to the drugs or / and health products used for preventing or / and treating hepatic fibrosis. Experimental materials used in the invention are derived from original plants which are widely available; and the enzymatic hydrolysates are low in cost, definite in extract activity and have good practical value.

The invention specifically relates to application of mogrol to preparation of drugs or / and health products used for preventing or / and treating hepatic fibrosis, belonging to the field of crude drugs. Experimental results prove that mogrol can substantially inhibit deposition of hepatocyte collagen, suppress hyperplasia of hepatic fibroblasts, reduce secretion of alpha-SMA in hepatic tissue and substantially improve hepatic fibrosis. Mogrol is definite in structure, good in stability, easily controllable in quality and cost, derived from the extract of natural plants, clear in activity, low in toxicity and side effect, provides a novel option and means for treatment or / and prevention of hepatic fibrosis, and has good practical value.

The invention belongs to the technical field of medicine, and relates to a 15-methylene-14-deoxy-11,12-dehydro-andrographolide derivative. Experiments prove that the compounds obviously inhibit the migration and activation of hepatic stellate cells, obviously inhibit the mesenchymal transition of TGF-beta 1-induced human alveolar type II epithelial cells A549, obviously inhibit the mesenchymal transition of human renal cortex proximal convoluted tubule epithelial cells HK-2, and obviously inhibit the migration of angiotensin II (Ang II)-induced primary human cardiac fibroblasts HCFB. The compound is taken as an active ingredient for preparing anti-fibrosis drugs, has high efficiency and low toxicity, provides a new drug route for the treatment and prevention of fibrosis-related diseases, and thus the selectable range of clinical drugs is expanded, so that the derivative has a good application and development prospect.

Disclosed is use of andrographolide derivative as shown by general formula 1 in manufacture of medicaments for anti-hepatitis C virus, and preventing and treating immunological liver damage caused by virus infection and different chemical liver damage.

The invention belongs to the technical field of medicines, and discloses an application of an andrographolide derivative in the preparation of medicaments for preventing and treating various fibrosis.The invention relates to an application of 14-deoxy-11, 12-dehydrogenation-7, 8-ene-andrographolide and a 15-subunit substituted derivative. Experiments prove that the compound obviously inhibits themigration and activation of hepatic stellate cells; significantly inhibits TGF-beta1 induced mesenchymal transformation of human alveolar type II epithelial cells A549; significantly inhibits TGFbeta1 induced HK-2 mesenchymal transformation of human renal cortical proximal tubular epithelial cells; inhibits the migration of HCFB in primary human cardiac fibroblasts induced by angiotensin II (AngII). In a model of common bile duct ligation in mice, a model of pulmonary fibrosis induced by silica in mice and a model of unilateral ureteral ligation in mice, the compound shows good anti-fibrosisactivity in vivo. The compound is used as an active ingredient for preparing the anti-fibrosis medicament, has high efficiency and low toxicity, and has a good prospect of developing various anti-fibrosis medicaments.

The invention discloses a monatomic copper catalyst as well as a gram-level preparation method and application thereof to selective reduction of functional organic molecules. According to the method,glyoxal and melamine are subjected to condensation reaction to form a Schiff base functional group, so that the Schiff base functional group can be efficiently complexed with a copper source; furtherthe complexed copper source is sintered into a monatomic copper catalyst, so that monatomic copper is stably embedded into a framework of carbon nitride; according to the method, a common copper source and melamine are adopted as reaction raw material agents, so that the raw material of the synthesis reaction is low in cost and easy to obtain, an easily complexed Schiff base functional group is formed through the condensation reaction of glyoxal and melamine, the copper source is uniformly dispersed in a ligand skeleton, and the ligand is sintered to form a carbon nitride skeleton to stabilizethe copper source.

The invention discloses cordyceps cicadae rhzomorph as well as a preparation method and application thereof. The cordyceps cicadae rhzomorph consists of more than 99 weight percent of polysaccharides; and the polysaccharides comprise mannose, galactose, rhamnose and glucose in a mass ratio of (45.20-50.20):(5.50-8.30):(2.10-2.60):(0.80-1.30). The preparation method of the cordyceps cicadae rhzomorph comprises the steps of extracting crude paecilomyces cicadae mycelium polysaccharides by water extraction and alcohol precipitation, removing protein by an enzyme-Sevage combination method, dialyzing, purifying by anion exchange chromatography and gel filtration chromatography, and performing vacuum freeze drying to separate the purified components, thus obtaining paecilomyces cicadae mycelium polysaccharides, namely cordyceps cicadae rhzomorph. Component analysis, structural identification and immunity researches on the purified polysaccharides show that the paecilomyces cicadae mycelium polysaccharides have relatively strong anti-oxidation activity, can be used as antioxidants or used for preparing antioxidants, and can be widely applied to cosmetics, health-care food, animal feed additives, medicine and the like.

The invention discloses a Chinese cordyceps sinensis protein polysaccharide and preparation and application thereof. The Chinese cordyceps sinensis protein polysaccharide is composed of polysaccharide with 55%-60% weight percentage and protein with 40%-45% weight percentage; and the ingredients of the polysaccharide are mannose, ribose, glucose, galactose, xylose and arabinose; the ratio of amount of substances among the mannose, the ribose, the glucose, the galactose, the xylose and the arabinose is 6.42-6.51: 2.20-2.32: 65.85-65.95: 2.10-2.18: 4.20-4.30. The Chinese cordyceps sinensis protein polysaccharide preparation method comprises the following steps: extracting the Chinese cordyceps sinensis protein polysaccharide by aqueous extract and alcohol precipitation, removing the protein, dialyzing, exchanging chromatography by anion and purifying gel filter layer chromatography through an enzyme-Sevage combination method, and freezing, drying and separating purification components in vacuum, and the Chinese cordyceps sinensis protein polysaccharide is acquired. According to the preparation and the application thereof, proximate analysis, structural identification and immunologic function study are carried out on the components of polysaccharide after purification, and the facts that the Chinese cordyceps sinensis protein polysaccharide has strong immunoregulation activity and is a potential immunological enhancement substance are discovered.

The invention discloses a black nightshade extract, and a separation and extraction method and application of the black nightshade extract in preparation of an anti-inflammatory and analgesic drug. The separation and extraction method of the black nightshade extract comprises the following steps: smashing a black nightshade whole plant, adding water or ethanol solution, carrying out extraction a plurality of times, filtering extract, mixing filtrate, and concentrating into extract which is the black nightshade extract. An organic solvent can be added for extraction after the filtrate is mixed,then an organic solvent layer is taken and then is concentrated into extract. The black nightshade extract disclosed by the invention has the advantages that the separation and extraction method is simple, efficient and energy-saving, and the black nightshade extract has definite anti-inflammatory and analgesic effects and can be used for preparing drugs for related applications.

The invention belongs to the technical field of medicine, discloses the application of andrographolide derivatives in the preparation of medicines for preventing and treating fibrosis of various tissues and organs of human body, and relates to the structure-modified derivatives of andrographolide decahydronaphthalene. It has the structure of general formula II. Experiments have proved that this type of compound significantly inhibits the migration and activation of hepatic stellate cells LX‑2; significantly inhibits TGF‑β1-induced mesenchymal transition (EMT) of human alveolar type II-like cells A549 and kidney epithelial cells HK‑2. Significantly inhibited the migration of primary human cardiac fibroblasts HCFB induced by angiotensin Ⅱ (Ang Ⅱ). Using this type of compound as an active ingredient to prepare anti-fibrosis drugs of human tissues and organs has high efficiency and low toxicity, and provides a new drug approach for the treatment and prevention of diseases related to fibrosis, thereby expanding the optional range of clinical medication, and has the advantages of Good prospects for application development.

The invention relates to a 2, 3-dihydroxy cinnamomum lactone derivative and an anti-inflammatory effect thereof. The 2, 3-dihydroxy cinnamomum lactone derivative is structurally characterized in that in the 2, 3-dihydroxy cinnamomum lactone derivative, R1 is angelica acyl, acetyl, cinnamoyl, succinic monoacyl, trifluoroacetic acyl, sulfur acyl or H, and R2 is acetyl, cinnamoyl, succinic monoacyl,trifluoroacetic acyl, sulfur acyl or H. The invention also provides application of the prepared 2, 3-dihydroxy cinnamomum lactone derivative to inflammation treatment medicine. A first compound (R1=R2=H) and a second compound (R1 is angelica acyl, and R2 is H) prepared form natural plants have good stability and good anti-inflammatory activity and can be used for preparing medicine for treating corresponding diseases. The activity is explicit, experimental materials can be easily obtained, and the cost is low.

The invention belongs to the technical field of medicine and relates to 15-methylene-14-deoxy-11,12-dehydro-andrographolide derivatives. It has been proved by experiments that this type of compound significantly inhibits the migration and activation of hepatic stellate cells; significantly inhibits TGF‑β1-induced mesenchymal transition of human alveolar type II epithelial cells A549; significantly inhibits human renal cortical proximal tubule epithelial cells HK‑2 mesenchymal transition; significantly inhibits angiotensin Ⅱ (AngⅡ)-induced migration of primary human cardiac fibroblasts HCFB. Using this type of compound as an active ingredient to prepare anti-fibrosis drugs has high efficiency and low toxicity, and provides a new drug approach for the treatment and prevention of fibrosis-related diseases, thereby expanding the optional range of clinical drugs and having good application development prospect.

The invention relates to an application of total dendrobium crepidatum alkaloids in preparing a medicament for treating acute and chronic inflammation, acute and chronic arthritis or rheumatoid arthritis diseases, and the content of the total dendrobium crepidatum alkaloids is 80-91 percent; and shown through a great amount of experiments by an inventor, the total dendrobium crepidatum alkaloids have a good effect on inflammation treatment. The total dendrobium crepidatum alkaloids have better stability and good anti-inflammation activity, and can be used for preparing medicaments for treating corresponding diseases. The total dendrobium crepidatum alkaloids have clear activity, and the experimental materials come from plants, so that the cost is low.

The invention belongs to the technical field of medicine, discloses the application of andrographolide derivatives in the preparation of various drugs for the prevention and treatment of fibrosis, relates to 14-deoxy-11,12-dehydro-7,8-ene andrographolide and its 15‑subunit substituted derivatives. Experiments have proved that this type of compound significantly inhibits the migration and activation of hepatic stellate cells; significantly inhibits TGF-β1-induced human alveolar type II epithelial cell A549-mesenchymal transition; significantly inhibits TGF-β1-induced human renal cortical proximal tubule epithelium Mesenchymal transformation of cells HK‑2; inhibition of angiotensin Ⅱ (AngⅡ)-induced migration of primary human cardiac fibroblasts HCFB. In the mouse common bile duct ligation model, the silica-induced mouse pulmonary fibrosis model and the mouse unilateral ureteral ligation model, the compounds in this study all showed good anti-fibrosis activity in vivo. The compound is used as an active ingredient to prepare anti-fibrosis drugs, has high efficiency and low toxicity, and has a good prospect of developing anti-fibrosis drugs.

The invention belongs to the technical field of medicines, and discloses an application of herba andrographitis lactone decalin derivatives in preparing drugs for preventing and treating various tissue and organ fibrosis of human bodies, and relates to herba andrographitis lactone decalin structural modified derivatives. The herba andrographitis lactone decalin structural modified derivative has astructure as shown in general formula II. Experiments show that the compounds can significantly inhibit the migrating activation of hepatic stellate cells LX-2 and can significantly inhibit the mesenchymal transition (EMT) of TGF-beta 1 induced human alveolar type-II sample cells A549 and kidney epithelial cells HK-2. The compounds are used as active ingredients to prepare human tissue and organfibrosis-resisting drugs and are efficient and low in toxicity, and can provide a novel drug way for treating and preventing fibrosis related diseases, thereby enlarging the selection range of clinical medication, and having good application and development prospect. (Shown in the description).

The invention discloses a monoatomic / diatomic catalyst and a controllable synthesis method and application thereof. According to the method, firstly, a porous carbon nanosheet is prepared, precise regulation and control of an atomic-scale structure are achieved through simple synthesis conditions, and a catalytic mechanism can be deeply understood through clearer active centers and active sites; and the monoatomic / diatomic catalyst is applied to electrocatalytic reduction of carbon dioxide and shows excellent catalytic activity, and meanwhile, the monoatomic / diatomic catalyst is good in catalytic stability and low in preparation cost, has very good practical applicability, and has excellent application prospects in the field of electrocatalytic reduction of carbon dioxide.

The invention relates to a pharmaceutical composition for treating diabetes and its application, belonging to the technical field of medicine. The technical problem solved by the present invention is to provide a pharmaceutical composition for treating diabetes. The pharmaceutical composition for treating diabetes of the present invention, the active ingredient is composed of the following components by weight: 1-18 parts of pentagalloyl glucose, 1-12 parts of geniposide. The present invention combines PGG and geniposide in the prevention and treatment of diabetes and its complications, combines the advantages of both in hypoglycemic, anti-inflammatory, anti-oxidation, protection of islet cells, and alleviation of insulin resistance, and provides a new way for clinical treatment of diabetes. Drugs for its complications provide a more comprehensive and effective option. The experimental materials involved in the invention come from original plants, the original plants have a wide range, low cost, clear activity of the extract, less toxic and side effects, and wide practical value.

The invention discloses a single / dual-atom catalyst and a controllable synthesis method and application thereof. Firstly, porous carbon nanosheets are prepared. Through simple synthesis conditions, precise control of atomic-level structure is realized, and active centers and active sites are more clearly defined. It is conducive to a deeper understanding of the catalytic mechanism, and at the same time, it is applied to electrocatalytic carbon dioxide reduction, showing excellent catalytic activity, good catalytic stability, low preparation cost, and strong practical applicability, which can be used in The field of electrocatalytic carbon dioxide reduction has excellent application prospects.

The invention relates to a compound with effects of resisting inflammation and platelet activation and aggregation as well as a preparation method and application thereof. The compound has the structure of (25R)-26-oxy-beta-D-glucopyranose-5alpha-furostanol-3beta,12beta,22,26-tetraalcohol-3-oxy-beta-D-glucopyranose(1->2)[beta-D-glucopyranose(1->3)]-beta-D-glucopyranose(1->4)-beta-D-galapyranoside. The effects of the compound in the field of cardial vessels are comprehensively researched from platelet aggregation, platelet activation, platelet calcium ion variation, platelet activation signal transduction pathway and expression of platelet activation relevant inflammatory factors in the invention for the first time. Results show that the compound is a substance found to be with a strong effect on resisting platelet aggregation so far in the allium macrostemon saponin compounds, which has the stronger effect than that of aspirin with the same concentration; and the compound simultaneously has an obvious effect on resisting relevant platelet inflammations. The compound provided by the invention can be applied to medicines for treating thrombus and atherosclerosis.